LLY · 10-Q · 2026Q2 · Full report
Product Launch - Foundayo
ELI LILLY & Co · 2026-08-05 · Importance 33 · Surprise 42 · In source text
Lilly launched Foundayo (orforglipron) in the U.S. during the second quarter of 2026 for obesity treatment. The company submitted orforglipron for type 2 diabetes in the U.S., EU, and Japan, and has submitted it for obesity and/or type 2 diabetes in all major international markets. Near-term uptake will depend on additional regulatory approvals and the pace of adoption through new incretin channels and markets.
Key facts
- In the second quarter of 2026, the company launched Foundayo (orforglipron) in the U.S. for the treatment of obesity and submitted orforglipron for type 2 diabetes to the FDA. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | In the second quarter of 2026, the company launched Foundayo (orforglipron) in the U.S. for the treatment of obesity and submitted… |
| revenue | positive | probable | — | In the second quarter of 2026, the company launched Foundayo (orforglipron) in the U.S. for the treatment of obesity and submitted… |